Study Title: A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination with Durvalumab compared With Durvalumab as Maintenance Therapy in Subjects with Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy with Platinum, Etoposide and Durvalumab
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Mariam Alexander, at alexanma@musc.edu.Study Coordinator, Jessica Shealor, at shealorj@musc.edu.Trial opened at the following institutions: Medical University of South Carolina